Immix Biopharma to Participate in Upcoming Investor Conferences

Immix Biopharma to Participate in Upcoming Investor Conferences

Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsedrefractory AL Amyloidosis, today announced that it will present and host investor meetings at the following upcoming institutional investor conferences:

  • Leerink Partners 2026 Global Healthcare Conference being held March 8-11, 2026 in Miami Beach, FL.
  • The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami Beach, FL.

Company management will host one-on-one meetings during the conferences. Interested investors should contact their Leerink or Citizens representative to request meetings. A link to access replays, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.

About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that's supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a "digital filter" that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Company Contact
irteam@immixbio.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

IMMX
The Conversation (0)
Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled

Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled

KELOWNA, BC / ACCESS Newswire / November 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that final dosing has been completed on schedule with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral... Keep Reading...
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 5 Canadian Biotech Stocks in 2026

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.Here, the Investing News Network profiles the five best-performing Canadian biotech stocks... Keep Reading...
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 Small-cap Biotech Stocks in 2026

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has climbed back to multi-year highs in 2026, underscoring renewed strength in the biotech sector despite broader market volatility. As of November 4, the index stood at 7,463.68, up over 30 percent year-to-date. The rise shows that investors are... Keep Reading...
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

Bria-OTS+â„¢ demonstrates broad immune activation and sustained cancer-cell killing across multiple tumor modelsBriaPro data highlights BP-80 tolerability in primates and advances in tumor-targeted checkpoint inhibition briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or... Keep Reading...
Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH

Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH

(TheNewswire) Third pharmaceutical company relationship entered Kelowna, British Columbia November 4, 2026 TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an... Keep Reading...
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 

BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 

Four presentations highlight BriaCell's Bria-OTS+â„¢ cellular immunotherapy platform and BriaPro's CD80-based immunotherapy programsIn vitro Bria-OTS+ studies demonstrate immune-cell activation and tumor-cell killing across breast, prostate and lung cancer modelsBriaPro data describes BP-80... Keep Reading...

Interactive Chart

Latest Press Releases

Related News